【Abstract】Objective To study effects of different doses of tripterygium glycosides on serum leukotactin1(LKN1), retinol binding protein (RBP), matrix metalloproteinases9 (MMP9) and tissue inhibitor of metalloproteinase 1 (TIMP1) in patients with chronic glomerulonephritis.Methods 100 patients of chronic glomerulonephritis received therapy from March 2015 to March 2017 in our hospital were selected. According to random number table, those patients were divided into the A group (n=50) and the B group (n=50). On the basis of conventional treatment, the two groups were treated with Tripterygium Glycosides tablets. A group was given 15mg/ (kg.d) for 4 weeks, then take the 1mg/ (kg.d) for another 4 weeks. B group was given 1mg/ (kg.d). The changes of creatinine (sCr), urea nitrogen (BUN) and 24 h urinary protein and serum LKN1, RBP, MMP9 and TIMP1 were compared between the two groups before and after treatment. The clinical efficacy and adverse reactions were compared.Results After treatment, SCr, BUN and 24 h urine protein in the two groups were significantly lower than those before treatment (P＜005). SCr, BUN and 24 h urine protein in the A group were significantly lower than that of the B group(P＜005). After treatment, serum LKN1, RBP and TIMP1 in the two groups were significantly lower than those before treatment. The serum MMP9 increased significantly(P＜005). The serum LKN1, RBP and TIMP1 in A group were significantly lower than that of the B group, and serum MMP9 was significantly higher than that of the B group (P＜005). The total effective rate in the A group was significantly higher than that of B group(P＜005). There was no significant difference in the incidence of adverse reactions between the two groups(P＞005).Conclusion In patients with chronic glomerulonephritis, increase the initial dose of tripterygium glycosides is more helpful to improve renal function and clinical efficacy. The underlying mechanism may be related to the more effective reduction of serum LKN1 and RBP levels, increased MMP9 activity, and inhibition of TIMP1 expression, and did not increase adverse drug reactions.